Neumora Therapeutics, Inc. Common Stock

NMRANASDAQUSD
1.63 USD
0.12 (6.86%)AT CLOSE (11:59 AM EDT)
1.69
0.07 (3.99%)
POST MARKET (AS OF 07:38 PM EDT)
Post Market
AS OF 07:38 PM EDT
1.69
0.07 (3.99%)
🔴Market: CLOSED
Open?$1.75
High?$1.75
Low?$1.61
Prev. Close?$1.75
Volume?864.6K
Avg. Volume?1.3M
VWAP?$1.68
Rel. Volume?0.67x
Bid / Ask
Bid?$1.39 × 100
Ask?$1.99 × 100
Spread?$0.60
Midpoint?$1.69
Valuation & Ratios
Market Cap?302.0M
Shares Out?185.3M
Float?68.9M
Float %?41.2%
P/E Ratio?N/A
P/B Ratio?4.27
EPS?-$1.20
Dividend?0.00%
Ex-Dividend?N/A

Neumora Therapeutics, Inc. Common Stock (NMRA) trades at $1.63 per share. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On valuation, NMRA trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
Employees
92
Market Cap
302.0M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2023-09-15
Address
260 ARSENAL PLACE, SUITE 1
WATERTOWN, MA 02472
Phone: (857) 760-0900
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bearish(-3/3)
Medium-Term (Wave)? Bearish(-3/3)
Short-Term (Ripple)? Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
50
Short Sent.?
41
Piotroski F-Score?0/9Weak
Altman Z-Score?-12.90Distress
Confidence?56%Low
Full Fundamental Analysis →
Short InterestElevated
Short % of Float?7.11%Elevated
Short Interest?4.9M
Days to Cover?3.0
Free Float68.9M
Avg Daily Volume1.6M
Settlement Date2026-05-15
Financial Health
Current Ratio?5.09Strong
Quick Ratio?5.09Strong
Cash Ratio?4.88Strong
Debt/Equity?0.75Moderate
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A
P/B?
Peers
100
S&P
42
4.27FAIR
P/S?
N/A
P/FCF?
N/A
EV/EBITDA?
S&P
97
-0.9CHEAP
EV/Sales?
N/A
Returns & Efficiency
ROE?
S&P
3
-314.7%WEAK
ROA?
S&P
3
-144.5%WEAK
Cash Flow & Enterprise
FCF?$-193412000
Enterprise Value?$207.9M
Fundamentals ratios updated end of day